Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

NASDAQ:BBLG

Bone Biologics Corporation

Last Close

1.42

30/08 20:00

Market Cap

1.25M

Beta: 0.81

Volume Today

16.04K

Avg: 206.11K

PE Ratio

−1.92

PFCF: −0.17

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics